<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330277</url>
  </required_header>
  <id_info>
    <org_study_id>BH 06-2018</org_study_id>
    <nct_id>NCT01330277</nct_id>
  </id_info>
  <brief_title>Biomarkers for Hunter Syndrome</brief_title>
  <acronym>BioHunter</acronym>
  <official_title>Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to establish Hunter Syndrom
      biomarker/s and to explore the clinical robustness, specificity, and long-term variability of
      these biomarker/s
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucopolysaccharides are long chains of sugar carbohydrates, found within the cells that help
      build bone, cartilage, tendons, cornea, skin, and connective tissue. Glycosaminoglycans
      (GAGs) are also found in the fluids that lubricate joints. Mucopolysaccharidosis (MPS) are
      part of the Lysosomal Storage Disorder (LSD) family, a group of more than 40 genetic
      diseases, and occur when a particular enzyme exists in a small quantity or is missing
      altogether. The effect is the accumulation of GAGs in the cells, blood, and connective
      tissues, resulting in permanent and progressive cellular damage which affects appearance,
      physical abilities, organ and system functioning and, in most cases, mental development.

      MPS2 (also called Hunter syndrome) is a hereditary, progressive, multisystemic disorder,
      caused by mutations in the IDS gene coding for the enzyme iduronate sulfatase (Ids). It is
      the only type of mucopolysaccharidosis that is X-linked, therefore, if mothers are carriers,
      there is a 50 percent chance for males to be born with the disease.

      MPS2 has a wide range of symptoms that vary in severity, which can be managed with enzyme
      replacement therapy (ERT). ERT is unable to cross the blood-brain barrier, therefore it
      addresses strictly extra-neurological manifestations. On this note, further efforts are being
      made to develop novel therapies, in the attempt to stop the disease progression and to offer
      a better quality of life to the patients.

      As MPS2 is very rare and many medical professionals only see a few or no patients in their
      lifelong practice, genetic testing is crucial for diagnosis. This study thrives to identify,
      validate, and monitor potential biomarker/s for MPS2 in genetically confirmed samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying MPS II biomarkers</measure>
    <time_frame>36 weeks</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the clinical robustness, specificity, and long-term variability of MPS II biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hunter Syndrome</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>Hunter's Syndrome, Mild Form</condition>
  <condition>Hunter's Canal Syndrome</condition>
  <arm_group>
    <arm_group_label>Participants with Hunter syndrome</arm_group_label>
    <description>Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male participants with genetically confirmed Hunter syndrome (Mucopolisaccharidosis type 2
        or MPS2)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Male individuals

          -  Informed consent is obtained from the participant's parent/legal guardian

          -  The participant is aged between 2 months and 50 years of age

          -  The diagnosis of MPS II is genetically confirmed by CENTOGENE

        EXCLUSION CRITERIA:

          -  Females

          -  Informed consent is not provided by the participant's parent/legal guardian

          -  The participant is younger than 2 months or older than 50 years of age

          -  The diagnosis of MPS II is not genetically confirmed by CENTOGENE
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)3818011359</phone>
    <email>Volha.Skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radwa Elkomi</last_name>
    <phone>+49 (0)38180113544</phone>
    <email>Radwa.Elkomi@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Cancun</city>
        <state>Quintana Roo</state>
        <zip>77533</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Gaviño Vergara, MD</last_name>
      <phone>+52 (0)19982423722</phone>
      <email>drgavino@live.com.mx</email>
    </contact>
    <investigator>
      <last_name>Alejandro Gaviño Vergara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pediatrico de Sinaloa</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Ernesto Duenas Arias, MD</last_name>
      <phone>+52 (0)16671023451</phone>
      <email>jedanet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Ernesto Duenas Arias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Lopez, MD</last_name>
      <phone>+52 (0)14491898445</phone>
      <email>jasad16@yahoo.com.mx</email>
    </contact>
    <investigator>
      <last_name>Jaime Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Tampaulipas</name>
      <address>
        <city>Ciudad Victoria</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Barraza, MD</last_name>
      <phone>+52 (0)18342588092</phone>
      <email>astridbarraza@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Astrid Barraza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <removed_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Pakistan</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Sri Lanka</country>
  </removed_countries>
  <link>
    <url>https://www.centogene.com/</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunter Disease</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

